CitiusTech CEO Rajan Kohli is resigning by late August 2026, with Dhaval Shah appointed as Acting CEO and Shyam Karunakaran as President. This leadership transition occurs during ongoing takeover discussions, with reports linking the healthcare technology firm to potential buyers such as Cognizant. As a private entity backed by EQT and Bain, the firm is navigating a significant change in its ownership and management path.
CitiusTech, a notable firm in the healthcare technology services sector, has announced a major leadership restructuring. Rajan Kohli is set to step down as Chief Executive Officer by the end of August 2026 to pursue other opportunities. In his place, Dhaval Shah has been named the Acting Chief Executive Officer, while Shyam Karunakaran takes on the role of President. Both incoming leaders have internal experience, with Shah previously managing the MedTech and Life Sciences divisions, and Karunakaran leading the Healthcare Payer and Platforms business.
Strategic Transition During Takeover Talks
This leadership change arrives at a sensitive time for the company, which is currently a private entity backed by private equity firms EQT and Bain. Industry reports have frequently linked CitiusTech to potential takeover discussions with large IT services players, including Cognizant. Such leadership transitions in private equity-backed companies are often part of a broader strategy to streamline operations or prepare the organization for a change in ownership. For the broader IT services ecosystem in India, this development is a key monitorable as it highlights potential consolidation within the niche healthcare-focused technology space.
Company Performance and Sector Focus
CitiusTech has reported strong operational performance in the fiscal year 2026, placing it among the top-tier players in technology services. The company expects this business momentum to continue into the 2027 fiscal year. A significant factor in its growth has been the rising demand for healthcare-specific artificial intelligence (AI) solutions, as enterprises look to deploy AI for complex clinical and operational challenges. With a workforce of over 7,700 professionals and relationships with more than 140 global enterprises, the company remains a significant player in digital health transformation.
Risks and Future Monitorables
While the internal succession aims to ensure business continuity, the combination of a leadership change and ongoing acquisition talks introduces specific execution risks. For any potential acquirer, maintaining client relationships and ensuring the retention of senior talent during a transition period is vital. Investors and industry observers in the IT sector should watch for further updates regarding the potential acquisition, as any formal deal could influence competitive dynamics within the healthcare IT services market. The stability of the leadership team during this period of uncertainty will be crucial for the company to maintain its current growth trajectory.